TY - JOUR
T1 - Use of a dynamic in vitro lipolysis model to rationalize oral formulation development for poor water soluble drugs
T2 - Correlation with in vivo data and the relationship to intra-enterocyte processes in rats
AU - Dahan, Arik
AU - Hoffman, Amnon
N1 - Funding Information:
This work is a part of Arik Dahan Ph.D dissertation. This study was supported by the Israeli Consortium of Pharmalogica. The authors thank Dr. Bashir Qadri and Inbal Yifrach for technical support, and Dr. Josh Backon and Pavel Gershkovich for constructive comments. A. Hoffman is affiliated with David R. Bloom Center of Pharmacy.
PY - 2006/9/1
Y1 - 2006/9/1
N2 - Purpose. To examine the correlation between the in vitro solubilization process of lipophilic compounds from different lipid solutions and the corresponding in vivo oral bioavailability data. In particular, to assess the influence of intra-enterocyte processes (metabolism and lymphatic absorption) on this correlation. Materials and Methods. The dissolution of progesterone and vitamin D3 in long (LCT), medium (MCT) and short (SCT) chain triglyceride solutions were tested in a dynamic in vitro lipolysis model. The absolute oral bioavailability of the drugs from the tested formulations was investigated in rats. Vitamin D3 bioavailability was also examined following lymphatic transport blockage induced by cycloheximide (3 mg/kg). Results. The dynamic in vitro lipolysis experiments indicated a rank order of MCT > LCT > SCT for both progesterone and vitamin D3. The bioavailability of progesterone correlated with the in vitro data, despite its significant pre-systemic metabolism. For vitamin D3, an in vivo performance rank order of LCT > MCT > SCT was obtained. However, when the lymphatic transport was blocked the bioavailability of vitamin D3 correlated with in vitro data. Conclusions. The in vitro lipolysis model is useful for optimization of oral lipid formulations even in the case of pre-systemic metabolism in the gut. However, when lymphatic transport is a significant route of absorption, the in vitro lipolysis data may not be predictive for actual in vivo absorption.
AB - Purpose. To examine the correlation between the in vitro solubilization process of lipophilic compounds from different lipid solutions and the corresponding in vivo oral bioavailability data. In particular, to assess the influence of intra-enterocyte processes (metabolism and lymphatic absorption) on this correlation. Materials and Methods. The dissolution of progesterone and vitamin D3 in long (LCT), medium (MCT) and short (SCT) chain triglyceride solutions were tested in a dynamic in vitro lipolysis model. The absolute oral bioavailability of the drugs from the tested formulations was investigated in rats. Vitamin D3 bioavailability was also examined following lymphatic transport blockage induced by cycloheximide (3 mg/kg). Results. The dynamic in vitro lipolysis experiments indicated a rank order of MCT > LCT > SCT for both progesterone and vitamin D3. The bioavailability of progesterone correlated with the in vitro data, despite its significant pre-systemic metabolism. For vitamin D3, an in vivo performance rank order of LCT > MCT > SCT was obtained. However, when the lymphatic transport was blocked the bioavailability of vitamin D3 correlated with in vitro data. Conclusions. The in vitro lipolysis model is useful for optimization of oral lipid formulations even in the case of pre-systemic metabolism in the gut. However, when lymphatic transport is a significant route of absorption, the in vitro lipolysis data may not be predictive for actual in vivo absorption.
KW - Bioavailability
KW - In vitro lipolysis
KW - Intestinal absorption
KW - Lipid based formulations
KW - Lipophilic drugs
KW - Lymphatic transport
KW - Pre-systemic metabolism
UR - http://www.scopus.com/inward/record.url?scp=33750592309&partnerID=8YFLogxK
U2 - 10.1007/s11095-006-9054-x
DO - 10.1007/s11095-006-9054-x
M3 - Article
C2 - 16902814
AN - SCOPUS:33750592309
SN - 0724-8741
VL - 23
SP - 2165
EP - 2174
JO - Pharmaceutical Research
JF - Pharmaceutical Research
IS - 9
ER -